Sweden
Airsonett AB, with its slogan "A Breath of New Life", is a Swedish medical device company founded in 2010. The company is at the forefront of developing non-pharmaceutical treatments for allergic asthma and eczema through its innovative product, Airsonett AIR4.
Supported by Industrifonden, SEB Venture Capital, Magnus Lundberg, and Fåhraeus Startup & Growth, Airsonett has made significant strides in its commitment to improving the health-related quality of life for individuals suffering from allergic respiratory conditions.
Airsonett's patent portfolio and substantial investment in clinical research and product development underscore the company’s dedication to advancing its technology. The latest venture round investment of kr20.00M on 30 July 2022 by Industrifonden, SEB Venture Capital, and Fåhraeus Startup and Growth further validates the confidence of investors in the company's potential.
Notably, Airsonett's flagship product, Air4, creates a protective sleep zone shielded from allergens, offering individuals a chance to experience clean air during sleep. This technology is specifically designed for those with severe atopic asthma and is recommended as an effective at-home treatment for allergic asthma, rhinitis, and eczema. Air4 is free from pharmacological side effects, making it safe for both adults and children.
Airsonett's commitment to providing a safe and effective solution for those suffering from allergic respiratory conditions positions the company as a key player in the healthcare and information technology industries. With a mission to ensure everyone can breathe perfectly clean air
